Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience

F. Navid, A. D. Mosijczuk, D. R. Head, M. J. Borowitz, A. J. Carroll, J. M. Brandt, M. P. Link, M. K. Rozans, Gregory Thomas, M. R. Schwenn, D. J. Shields, T. J. Vietti, D. J. Pullen

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Five pediatric patients are described with acute lymphoblastic leukemia (ALL) who at presentation had clinical findings suggestive of B cell ALL and lymphoblasts with FAB L3 morphology and the characteristic t(8;14)(q24;q32). However, the leukemia cells of all five patients failed to express surface immunoglobulin (sIg) and kappa or lambda light chains. Based on initial immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy. These four patients were switched to B cell ALL treatment protocols once cytogenetic results became available revealing the 8;14 translocation. The fifth case was treated with B cell ALL therapy from the outset. Four of the five patients are in complete remission at 64, 36, 29 and 13 months from diagnosis. One patient relapsed and died 6 months after initial presentation. These five unusual cases with clinical B cell ALL, the t(8;14), and FAB L3 morphology, but negative sIg, demonstrate the importance of careful and multidisciplinary evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis. Future identification of patients with this profile will allow us to expand our knowledge regarding prognostic significance and optimal treatment for this rare subgroup of patients.

Original languageEnglish (US)
Pages (from-to)135-141
Number of pages7
JournalLeukemia
Volume13
Issue number1
StatePublished - 1999

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
B-Lymphocytes
Immunophenotyping
B-Cell Antigen Receptors
Histocytochemistry
Cytogenetic Analysis
Clinical Protocols
Cytogenetics
Leukemia
Light
Drug Therapy
Therapeutics

Keywords

  • B cell acute lymphoblastic leukemia
  • B-precursor actue lymphoblastic leukemia
  • t(8;14)

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Navid, F., Mosijczuk, A. D., Head, D. R., Borowitz, M. J., Carroll, A. J., Brandt, J. M., ... Pullen, D. J. (1999). Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience. Leukemia, 13(1), 135-141.

Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype : The Pediatric Oncology Group experience. / Navid, F.; Mosijczuk, A. D.; Head, D. R.; Borowitz, M. J.; Carroll, A. J.; Brandt, J. M.; Link, M. P.; Rozans, M. K.; Thomas, Gregory; Schwenn, M. R.; Shields, D. J.; Vietti, T. J.; Pullen, D. J.

In: Leukemia, Vol. 13, No. 1, 1999, p. 135-141.

Research output: Contribution to journalArticle

Navid, F, Mosijczuk, AD, Head, DR, Borowitz, MJ, Carroll, AJ, Brandt, JM, Link, MP, Rozans, MK, Thomas, G, Schwenn, MR, Shields, DJ, Vietti, TJ & Pullen, DJ 1999, 'Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience', Leukemia, vol. 13, no. 1, pp. 135-141.
Navid, F. ; Mosijczuk, A. D. ; Head, D. R. ; Borowitz, M. J. ; Carroll, A. J. ; Brandt, J. M. ; Link, M. P. ; Rozans, M. K. ; Thomas, Gregory ; Schwenn, M. R. ; Shields, D. J. ; Vietti, T. J. ; Pullen, D. J. / Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype : The Pediatric Oncology Group experience. In: Leukemia. 1999 ; Vol. 13, No. 1. pp. 135-141.
@article{f72135593fbc430496121067db0ccde2,
title = "Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience",
abstract = "Five pediatric patients are described with acute lymphoblastic leukemia (ALL) who at presentation had clinical findings suggestive of B cell ALL and lymphoblasts with FAB L3 morphology and the characteristic t(8;14)(q24;q32). However, the leukemia cells of all five patients failed to express surface immunoglobulin (sIg) and kappa or lambda light chains. Based on initial immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy. These four patients were switched to B cell ALL treatment protocols once cytogenetic results became available revealing the 8;14 translocation. The fifth case was treated with B cell ALL therapy from the outset. Four of the five patients are in complete remission at 64, 36, 29 and 13 months from diagnosis. One patient relapsed and died 6 months after initial presentation. These five unusual cases with clinical B cell ALL, the t(8;14), and FAB L3 morphology, but negative sIg, demonstrate the importance of careful and multidisciplinary evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis. Future identification of patients with this profile will allow us to expand our knowledge regarding prognostic significance and optimal treatment for this rare subgroup of patients.",
keywords = "B cell acute lymphoblastic leukemia, B-precursor actue lymphoblastic leukemia, t(8;14)",
author = "F. Navid and Mosijczuk, {A. D.} and Head, {D. R.} and Borowitz, {M. J.} and Carroll, {A. J.} and Brandt, {J. M.} and Link, {M. P.} and Rozans, {M. K.} and Gregory Thomas and Schwenn, {M. R.} and Shields, {D. J.} and Vietti, {T. J.} and Pullen, {D. J.}",
year = "1999",
language = "English (US)",
volume = "13",
pages = "135--141",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype

T2 - The Pediatric Oncology Group experience

AU - Navid, F.

AU - Mosijczuk, A. D.

AU - Head, D. R.

AU - Borowitz, M. J.

AU - Carroll, A. J.

AU - Brandt, J. M.

AU - Link, M. P.

AU - Rozans, M. K.

AU - Thomas, Gregory

AU - Schwenn, M. R.

AU - Shields, D. J.

AU - Vietti, T. J.

AU - Pullen, D. J.

PY - 1999

Y1 - 1999

N2 - Five pediatric patients are described with acute lymphoblastic leukemia (ALL) who at presentation had clinical findings suggestive of B cell ALL and lymphoblasts with FAB L3 morphology and the characteristic t(8;14)(q24;q32). However, the leukemia cells of all five patients failed to express surface immunoglobulin (sIg) and kappa or lambda light chains. Based on initial immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy. These four patients were switched to B cell ALL treatment protocols once cytogenetic results became available revealing the 8;14 translocation. The fifth case was treated with B cell ALL therapy from the outset. Four of the five patients are in complete remission at 64, 36, 29 and 13 months from diagnosis. One patient relapsed and died 6 months after initial presentation. These five unusual cases with clinical B cell ALL, the t(8;14), and FAB L3 morphology, but negative sIg, demonstrate the importance of careful and multidisciplinary evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis. Future identification of patients with this profile will allow us to expand our knowledge regarding prognostic significance and optimal treatment for this rare subgroup of patients.

AB - Five pediatric patients are described with acute lymphoblastic leukemia (ALL) who at presentation had clinical findings suggestive of B cell ALL and lymphoblasts with FAB L3 morphology and the characteristic t(8;14)(q24;q32). However, the leukemia cells of all five patients failed to express surface immunoglobulin (sIg) and kappa or lambda light chains. Based on initial immunophenotyping results consistent with B-precursor ALL, four of these cases were initially treated with conventional ALL chemotherapy. These four patients were switched to B cell ALL treatment protocols once cytogenetic results became available revealing the 8;14 translocation. The fifth case was treated with B cell ALL therapy from the outset. Four of the five patients are in complete remission at 64, 36, 29 and 13 months from diagnosis. One patient relapsed and died 6 months after initial presentation. These five unusual cases with clinical B cell ALL, the t(8;14), and FAB L3 morphology, but negative sIg, demonstrate the importance of careful and multidisciplinary evaluation of leukemic cells with morphology, cytochemistry, immunophenotyping and cytogenetic analysis. Future identification of patients with this profile will allow us to expand our knowledge regarding prognostic significance and optimal treatment for this rare subgroup of patients.

KW - B cell acute lymphoblastic leukemia

KW - B-precursor actue lymphoblastic leukemia

KW - t(8;14)

UR - http://www.scopus.com/inward/record.url?scp=0032945342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032945342&partnerID=8YFLogxK

M3 - Article

C2 - 10049049

AN - SCOPUS:0032945342

VL - 13

SP - 135

EP - 141

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -